{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:59:34Z","timestamp":1789088374507,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7917","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2022,7,7]]},"DOI":"10.1038\/s41586-022-04856-1","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T14:05:34Z","timestamp":1652709934000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":228,"title":["Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2"],"prefix":"10.1038","volume":"607","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-1922","authenticated-orcid":false,"given":"Ryuta","family":"Uraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-9031","authenticated-orcid":false,"given":"Shun","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6988-1975","authenticated-orcid":false,"given":"Masaki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9064-4699","authenticated-orcid":false,"given":"Emi","family":"Takashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Halfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Loeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Maemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5157","authenticated-orcid":false,"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-4729","authenticated-orcid":false,"given":"Zhongde","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Ujie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-020X","authenticated-orcid":false,"given":"Kiyoko","family":"Iwatsuki-Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlu","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-2937","authenticated-orcid":false,"given":"Seiya","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Yasuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-0771","authenticated-orcid":false,"given":"Hiroshi","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sakai-Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-873X","authenticated-orcid":false,"given":"Eisuke","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-9287","authenticated-orcid":false,"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9595-9657","authenticated-orcid":false,"given":"Masayuki","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-3397","authenticated-orcid":false,"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-1491","authenticated-orcid":false,"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"IASO study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Bennett-Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawson","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Kowalski-Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Eckard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gherasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf","family":"Gremel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Manthei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Zuniga","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Stoneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanna","family":"Sneeringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Warsinske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurika","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheta","family":"Godbole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Douek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-5439","authenticated-orcid":false,"given":"Ken","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-7877","authenticated-orcid":false,"given":"Aubree","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-3165","authenticated-orcid":false,"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9274-3853","authenticated-orcid":false,"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-9542","authenticated-orcid":false,"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"4856_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/d41586-021-03614-z","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway, E. & Ledford, H. How bad is Omicron? What scientists know so far. Nature 600, 197\u2013199 (2021).","journal-title":"Nature"},{"key":"4856_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-022-00676-6","volume":"22","author":"A Flemming","year":"2022","unstructured":"Flemming, A. Omicron, the great escape artist. Nat. Rev. Immunol. 22, 75 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"4856_CR3","unstructured":"World Health Organization. Weekly epidemiological update on COVID-19, 5 April 2022, https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19-5-april-2022 (2022)."},{"key":"4856_CR4","doi-asserted-by":"crossref","unstructured":"Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell 185,2103-2115.e19 (2022).","DOI":"10.1016\/j.cell.2022.04.035"},{"key":"4856_CR5","doi-asserted-by":"publisher","unstructured":"Lyngse, F. et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.01.28.22270044 (2022).","DOI":"10.1101\/2022.01.28.22270044"},{"key":"4856_CR6","doi-asserted-by":"publisher","unstructured":"Elliott, P. et al. Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.02.03.22270365 (2022).","DOI":"10.1101\/2022.02.03.22270365"},{"key":"4856_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"4856_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693\u2013699 (2022).","journal-title":"Nature"},{"key":"4856_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","volume":"603","author":"R Suzuki","year":"2022","unstructured":"Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700\u2013705 (2022).","journal-title":"Nature"},{"key":"4856_CR10","unstructured":"SARS-CoV-2 Variants of Concern and Variants Under Investigation in England, Technical Briefing 36 (UK Health Security Agency, 2022)."},{"key":"4856_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"4856_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","volume":"602","author":"E Cameroni","year":"2022","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664\u2013670 (2022).","journal-title":"Nature"},{"key":"4856_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"4856_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"4856_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMc2119407","volume":"386","author":"E Takashita","year":"2022","unstructured":"Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. N. Engl. J. Med. 386, 995\u2013998 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4856_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e286 (2020).","journal-title":"Cell"},{"key":"4856_CR17","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1126\/science.abe8499","volume":"370","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464\u20131468 (2020).","journal-title":"Science"},{"key":"4856_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"4856_CR19","doi-asserted-by":"publisher","first-page":"103589","DOI":"10.1016\/j.isci.2021.103589","volume":"25","author":"B Lubinski","year":"2022","unstructured":"Lubinski, B. et al. Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. iScience 25, 103589 (2022).","journal-title":"iScience"},{"key":"4856_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41586-021-04266-9","volume":"602","author":"A Saito","year":"2022","unstructured":"Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300\u2013306 (2022).","journal-title":"Nature"},{"key":"4856_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41586-021-04245-0","volume":"602","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294\u2013299 (2022).","journal-title":"Nature"},{"key":"4856_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085.e1012 (2020).","journal-title":"Cell"},{"key":"4856_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon 3rd","year":"2020","unstructured":"Dinnon, K. H. 3rd et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560\u2013566 (2020).","journal-title":"Nature"},{"key":"4856_CR24","doi-asserted-by":"publisher","first-page":"e3001284","DOI":"10.1371\/journal.pbio.3001284","volume":"19","author":"A Muruato","year":"2021","unstructured":"Muruato, A. et al. Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biol. 19, e3001284 (2021).","journal-title":"PLoS Biol."},{"key":"4856_CR25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"4856_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr","year":"2007","unstructured":"McCray, P. B. Jr et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"4856_CR27","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4856_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"4856_CR29","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/cid\/ciaa644","volume":"71","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"4856_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/RTI.0000000000000524","volume":"35","author":"S Simpson","year":"2020","unstructured":"Simpson, S. et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA\u2014Secondary Publication. J. Thorac. Imaging 35, 219\u2013227 (2020).","journal-title":"J. Thorac. Imaging"},{"key":"4856_CR31","doi-asserted-by":"publisher","first-page":"e2106535118","DOI":"10.1073\/pnas.2106535118","volume":"118","author":"M Imai","year":"2021","unstructured":"Imai, M. et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc. Natl Acad. Sci. USA 118, e2106535118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4856_CR32","doi-asserted-by":"publisher","unstructured":"Gilliland, T. et al. Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2021.07.26.453840 (2021).","DOI":"10.1101\/2021.07.26.453840"},{"key":"4856_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","volume":"28","author":"H Gruell","year":"2022","unstructured":"Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477\u2013480 (2022).","journal-title":"Nat. Med."},{"key":"4856_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","volume":"28","author":"SMS Cheng","year":"2022","unstructured":"Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med. 28, 486\u2013489 (2022).","journal-title":"Nat. Med."},{"key":"4856_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28544-w","volume":"13","author":"J Zou","year":"2022","unstructured":"Zou, J. et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat. Commun. 13, 852 (2022).","journal-title":"Nat. Commun."},{"key":"4856_CR36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","volume":"386","author":"A Rossler","year":"2022","unstructured":"Rossler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med. 386, 698\u2013700 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4856_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carreno","year":"2022","unstructured":"Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682\u2013688 (2022).","journal-title":"Nature"},{"key":"4856_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"4856_CR39","doi-asserted-by":"publisher","unstructured":"Uraki, R. et al. Therapeutic efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-1240227\/v1 (2022).","DOI":"10.21203\/rs.3.rs-1240227\/v1"},{"key":"4856_CR40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4856_CR41","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a non-covalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"4856_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"4856_CR43","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"4856_CR44","doi-asserted-by":"publisher","unstructured":"Majumdar, S. & Sarkar, R. Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.27558 (2021).","DOI":"10.1002\/jmv.27558"},{"key":"4856_CR45","doi-asserted-by":"publisher","unstructured":"Vieillard-Baron, A. et al. Epidemiological characteristics and severity of Omicron variant cases in the APHP critical care units. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.01.25.22269839 (2022).","DOI":"10.1101\/2022.01.25.22269839"},{"key":"4856_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706\u2013714 (2022).","journal-title":"Nature"},{"key":"4856_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26096-z","volume":"12","author":"M Ferren","year":"2021","unstructured":"Ferren, M. et al. Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. Nat. Commun. 12, 5809 (2021).","journal-title":"Nat. Commun."},{"key":"4856_CR48","doi-asserted-by":"publisher","first-page":"e1010340","DOI":"10.1371\/journal.ppat.1010340","volume":"18","author":"I Tomris","year":"2022","unstructured":"Tomris, I. et al. Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns. PLoS Pathog. 18, e1010340 (2022).","journal-title":"PLoS Pathog."},{"key":"4856_CR49","doi-asserted-by":"publisher","unstructured":"Case, J. et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.03.17.484787 (2022).","DOI":"10.1101\/2022.03.17.484787"},{"key":"4856_CR50","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001\u20137003 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4856_CR51","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"4856_CR52","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41590-021-01021-0","volume":"22","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. mRNA-1273 protects against SARS-CoV-2 Beta infection in nonhuman primates. Nat. Immunol. 22, 1306\u20131315 (2021).","journal-title":"Nat. Immunol."},{"key":"4856_CR53","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41564-019-0401-1","volume":"4","author":"A Yasuhara","year":"2019","unstructured":"Yasuhara, A. et al. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nat. Microbiol. 4, 1024\u20131034 (2019).","journal-title":"Nat. Microbiol."},{"key":"4856_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.virol.2020.05.015","volume":"548","author":"JB Case","year":"2020","unstructured":"Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E. & Diamond, M. S. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology 548, 39\u201348 (2020).","journal-title":"Virology"},{"key":"4856_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1148\/radiol.2020200230","volume":"295","author":"M Chung","year":"2020","unstructured":"Chung, M. et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 295, 202\u2013207 (2020).","journal-title":"Radiology"},{"key":"4856_CR56","doi-asserted-by":"publisher","first-page":"e0239403","DOI":"10.1371\/journal.pone.0239403","volume":"15","author":"K Itokawa","year":"2020","unstructured":"Itokawa, K., Sekizuka, T., Hashino, M., Tanaka, R. & Kuroda, M. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS ONE 15, e0239403 (2020).","journal-title":"PLoS ONE"},{"key":"4856_CR57","doi-asserted-by":"crossref","unstructured":"Quick, J. nCoV-2019 sequencing protocol. protocols.io https:\/\/www.protocols.io\/view\/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye (2020).","DOI":"10.17504\/protocols.io.bbmuik6w"},{"key":"4856_CR58","doi-asserted-by":"crossref","unstructured":"Itokawa, K. et al. nCoV-2019 sequencing protocol for Illumina V.5. protocols.io https:\/\/www.protocols.io\/view\/ncov-2019-sequencing-protocol-for-illumina-b2msqc6e?version_warning=no (2021).","DOI":"10.17504\/protocols.io.betejeje"},{"key":"4856_CR59","doi-asserted-by":"publisher","first-page":"100734","DOI":"10.1016\/j.eclinm.2021.100734","volume":"32","author":"S Yamayoshi","year":"2021","unstructured":"Yamayoshi, S. et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. eClinicalMedicine 32, 100734 (2021).","journal-title":"eClinicalMedicine"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04856-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T13:08:10Z","timestamp":1668344890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04856-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":59,"journal-issue":{"issue":"7917","published-print":{"date-parts":[[2022,7,7]]}},"alternative-id":["4856"],"URL":"https:\/\/doi.org\/10.1038\/s41586-022-04856-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1375091\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Shionogi, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation and Fuji Rebio. M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences and Carnival Corporation, and is on the scientific advisory boards of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, Immunome and Emergent BioSolutions. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}